Consequently,
Blood test could predict progression:
Essential
- A study reveals that a simple blood test, based on insulin resistance (the Tyg index), makes it possible to identify patients with Alzheimer’s most at risk of rapid cognitive decline. Moreover,
- This easily measurable insulin resistance would specifically act on the mechanisms of the disease from its early stages. For example,
- This biomarker could become a tool to predict the evolution of the disease and facilitate early management. Consequently,

. Consequently,
A trivial blood assay could make it possible to predict cognitive degradation in certain patients with Alzheimer’s, an always incurable disease but whose evolution largely depends on its early management. Similarly, It is at least the promise made by a team of Italian researchers from the University of Brescia. Furthermore, who published their results blood test could predict progression in the journal Alzheimer’s & Dementia and presented them during the 2025 congress of the European Neurology Academy (EAN).

.
A metabolic marker to predict the risk – Blood test could predict progression
To reach this new screening test, scientists relied on 315 non -diabetic patients with cognitive disorders, including 200 suffering from Alzheimer’s disease. All have undergone an assessment of their resistance to insulin via the Tyg (Triglyceride-Glucose) index. The patients were then followed for three years. Result: among people with light cognitive disorders linked to Alzheimer’s. those with the highest TYG scores have presented a cognitive decline four times faster than the others.

.
“Once a light cognitive impairment is diagnosed, families always wonder when it will progress, Explains the main researcher, Dre Bianca Gumina, in a press release. Our data show that a simple metabolic marker. easily measurable in the laboratory, can help identify more vulnerable subjects that could be candidates for targeted therapy or blood test could predict progression specific intervention strategies. “
An early intervention window?
The link between insulin resistance and the appearance of Alzheimer’s disease is already known. But its role in accelerating the disease has so far been little studied. This research therefore fills an important gap. highlighting a “Vulnerability specific to Alzheimer’s disease with metabolic stress during the prodromic phase”underlines Dre Guma. This early phase could become a key moment to act.

.
That’s not all: the Tyg index could also improve the selection of participants in clinical trials that test anti-amyloid or anti-mate treatments, the two key proteins that accumulate with Alzheimer.

.
In the absence of curative treatment, better predict the evolution of the disease would allow to anticipate support, to target interventions and perhaps, tomorrow, to slow down the loss of autonomy. According to the Alzheimer’s Disease International Foundation, 58 million people blood test could predict progression – including 1.3 million in France – live today with a form of dementia, of which Alzheimer’s most frequent.
Further reading: Fill the wrinkles from the inside thanks to the power of biotechnology – Estrie and Montérégie | RAGON RAGE RAGE LOVER explode – This tiny patch makes biopsy painless: a medical breakthrough that could transform care for millions of patients – A new very aggressive variant with disturbing symptoms? – International Cigler-Najjar Day: Treatment for testing.
